
DOI . ORG {
}
Title[redir]:
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial | Journal of Cancer Research and Clinical Oncology
Description:
Introduction While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. Methods This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Results Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. Conclusions The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
Matching Content Categories {📚}
- Education
- Health & Fitness
- Science
Content Management System {📝}
What CMS is doi.org built with?
Custom-built
No common CMS systems were detected on Doi.org, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of doi.org audience?
🏙️ Massive Traffic: 50M - 100M visitors per month
Based on our best estimate, this website will receive around 80,904,851 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Doi.org Make Money? {💸}
We can't see how the site brings in money.
Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org might be earning cash quietly, but we haven't detected the monetization method.
Keywords {🔍}
article, cancer, pubmed, google, scholar, lung, neoadjuvant, patients, cell, resectable, nonsmall, cas, chemotherapy, nsclc, response, oncol, data, treatment, phase, sintilimab, thorac, central, clinical, stage, trial, study, surgery, pathological, adverse, nonsmallcell, clin, management, singlearm, chemoimmunotherapy, rate, bronchopleural, fistula, ann, surg, jilin, potentially, liu, survival, pcr, events, advanced, access, privacy, cookies, content,
Topics {✒️}
stage iiia-n2 egfr-mutant month download article/chapter small-cell lung cancer stage iiia/iiib disease william wn jr small-cell lung cancers t-cell checkpoint inhibitors stage ii-iii stage iiia/iiib disease-free survival rate phase ii trial included treatment-naive patients advanced squamous nsclc lung cancer surgery major pathological response resectable lung cancer clinical oncology aims potentially resectable nsclc lung cancer resection resected lung cancer full article pdf privacy choices/manage cookies open window thoracostomy kewei ma systematic meta-analysis william wn zhiguang yang resectable locally advanced objective response rate pathologic complete response low-dose radiotherapy article sun stage iii sintilimab + nab-paclitaxel + carboplatin common terminology criteria response evaluation criteria neoadjuvant checkpoint blockade basic disease history advanced solid tumors disease control rate european economic area shi qiu code availability french database epithor erlotinib versus gemcitabine pathological effect interpretation clinical risk model neoadjuvant pd-1 inhibitor article journal xiaobo ma
Questions {❓}
- Chatwal MS, Tanvetyanon T (2018) Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?
Schema {🗺️}
WebPage:
mainEntity:
headline:Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
description:While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
datePublished:2022-02-22T00:00:00Z
dateModified:2022-02-22T00:00:00Z
pageStart:819
pageEnd:831
sameAs:https://doi.org/10.1007/s00432-021-03896-w
keywords:
Non-small cell lung cancer
Neoadjuvant
Chemoimmunotherapy
Sintilimab
Oncology
Cancer Research
Internal Medicine
Hematology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig3_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig4_HTML.png
isPartOf:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
type:
Periodical
PublicationVolume
publisher:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
description:While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
datePublished:2022-02-22T00:00:00Z
dateModified:2022-02-22T00:00:00Z
pageStart:819
pageEnd:831
sameAs:https://doi.org/10.1007/s00432-021-03896-w
keywords:
Non-small cell lung cancer
Neoadjuvant
Chemoimmunotherapy
Sintilimab
Oncology
Cancer Research
Internal Medicine
Hematology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig3_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig4_HTML.png
isPartOf:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
type:
Periodical
PublicationVolume
publisher:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
Organization:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(201)
- Check the income stats for https://link.springer.com/privacystatement
- What's the income generated by https://link.springer.com/article/10.1007/s00432-021-03896-w/#main each month?
- Income figures for https://link.springer.com
- What's the revenue for https://idp.springer.com/auth/personal/springernature?redirect_uri=https://link.springer.com/article/10.1007/s00432-021-03896-w?
- What are the total earnings of https://link.springer.com/article/10.1007/s00432-021-03896-w/#eds-c-header-nav?
- How much income is https://link.springer.com/journals/ earning monthly?
- How much cash flow does https://www.springernature.com/gp/authors have monthly?
- What's the total monthly financial gain of https://link.springernature.com/home/?
- What are the total earnings of https://link.springer.com/article/10.1007/s00432-021-03896-w/#eds-c-header-popup-search?
- Revenue of https://order.springer.com/public/cart
- What are the earnings of https://link.springer.com/article/10.1007/s00432-021-03896-w/?
- https://link.springer.com/article/10.1007/s00432-021-03896-w/journal/432's revenue stream
- Learn about the earnings of https://link.springer.com/article/10.1007/s00432-021-03896-w/#citeas
- How much revenue does https://link.springer.com/article/10.1007/s00432-021-03896-w/journal/432/aims-and-scope generate?
- What is the monthly revenue of https://submission.nature.com/new-submission/432/3?
- What is the monthly revenue of https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Chao-Sun-Aff1?
- Income figures for https://link.springer.com/article/10.1007/s00432-021-03896-w/#Aff1
- https://link.springer.com/article/10.1007/s00432-021-03896-w/#na1 income
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Yunpeng-Liu-Aff2 rake in every month?
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/#Aff2 gross monthly?
- How much profit does https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Peng-Zhang-Aff2 generate?
- Find out how much https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Xu-Wang-Aff1 earns monthly
- Explore the financials of https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Yinghui-Xu-Aff1
- How much income does https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Xingyu-Lin-Aff2 have?
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Xiaobo-Ma-Aff3 generate monthly?
- How much revenue does https://link.springer.com/article/10.1007/s00432-021-03896-w/#Aff3 bring in?
- What are the earnings of https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Ye-Guo-Aff1?
- How much income is https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Shi-Qiu-Aff1 earning monthly?
- https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Guoguang-Shao-Aff2's revenue stream
- What is the monthly revenue of https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Zhiguang-Yang-Aff2?
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/#auth-Kewei-Ma-Aff1 pull in monthly?
- Monthly income for https://orcid.org/0000-0003-2987-576X
- Get to know what's the income of https://link.springer.com/article/10.1007/s00432-021-03896-w/article/10.1007/s00432-021-03896-w/metrics
- What are the earnings of https://wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00432-021-03896-w?
- How much does https://link.springer.com/product/springer-plus pull in?
- Earnings of https://www.springernature.com/gp/librarians/licensing/agc/journals
- How much profit does https://link.springer.com/10.1186/s12957-023-03194-4?fromPaywallRec=true generate?
- What's the income of https://link.springer.com/10.1007/s10637-022-01324-5?fromPaywallRec=true?
- How much does https://link.springer.com/10.1038/s41467-025-59865-1?fromPaywallRec=true pull in?
- What's the financial intake of https://link.springer.com/article/10.1007/s00432-021-03896-w/subjects/cancer-immunotherapy?
- What's the financial outcome of https://link.springer.com/article/10.1007/s00432-021-03896-w/subjects/cancer-therapy?
- What's the financial intake of https://link.springer.com/article/10.1007/s00432-021-03896-w/subjects/cancer-therapeutic-resistance?
- Discover the revenue of https://link.springer.com/article/10.1007/s00432-021-03896-w/subjects/non-small-cell-lung-cancer
- What are the total earnings of https://link.springer.com/article/10.1007/s00432-021-03896-w/subjects/phase-iii-trials?
- How much profit is https://link.springer.com/article/10.1007/s00432-021-03896-w/subjects/small-cell-lung-cancer making per month?
- Profit of http://scholar.google.com/scholar_lookup?&title=An%20update%20on%20predictive%20biomarkers%20for%20treatment%20selection%20in%20non-small%20cell%20lung%20cancer&journal=J%20Clin%20Med&doi=10.3390%2Fjcm7060153&volume=20167&issue=6&publication_year=2018&author=Ahmadzada%2CT&author=Kao%2CS&author=Reid%2CG
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:STN:280:DC%2BB3cnjslajtw%3D%3D rake in every month?
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30566590
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20nivolumab%20in%20combination%20with%20S-1%2Fcapecitabine%20plus%20oxaliplatin%20in%20patients%20with%20previously%20untreated%2C%20unresectable%2C%20advanced%2C%20or%20recurrent%20gastric%2Fgastroesophageal%20junction%20cancer%3A%20interim%20results%20of%20a%20randomized%2C%20phase%20II%20trial%20%28ATTRACTION-4%29&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdy540&volume=30&issue=2&pages=250-258&publication_year=2019&author=Boku%2CN&author=Ryu%2CMH&author=Kato%2CK?
- http://scholar.google.com/scholar_lookup?&title=Global%20cancer%20statistics%202018%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries%20%28vol%2068%2C%20pg%20394%2C%202018%29&journal=Ca-a%20Cancer%20J%20Clin&doi=10.3322%2Fcaac.21609&volume=70&issue=4&pages=313-313&publication_year=2020&author=Bray%2CF&author=Ferlay%2CJ&author=Soerjomataram%2CI income
- http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20nivolumab%20%28N%29%20or%20nivolumab%20plus%20ipilimumab%20%28NI%29%20for%20resectable%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%3A%20clinical%20and%20correlative%20results%20from%20the%20NEOSTAR%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2019.37.15_suppl.8504&volume=37&issue=15_suppl&pages=8504-8504&publication_year=2019&author=Cascone%2CT&author=William%2CWN&author=Weissferdt%2CA income
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28838509 rake in every month?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572805 pull in monthly?
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Initial%20experience%20with%20lung%20cancer%20resection%20after%20treatment%20with%20T-cell%20checkpoint%20inhibitors&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2017.03.038&volume=104&issue=3&pages=e217-e218&publication_year=2017&author=Chaft%2CJE&author=Hellmann%2CMD&author=Velez%2CMJ?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30393603 pull in monthly?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193911
- How much money does http://scholar.google.com/scholar_lookup?&title=Combination%20chemotherapy%20and%20immunotherapy%20in%20metastatic%20non-small%20cell%20lung%20cancer%3A%20a%20setback%20for%20personalized%20medicine%3F&journal=Transl%20Lung%20Cancer%20Res&doi=10.21037%2Ftlcr.2018.07.15&volume=7&pages=S208-S210&publication_year=2018&author=Chatwal%2CMS&author=Tanvetyanon%2CT make?
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtVGmt7bL pull in monthly?
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29658848?
- Income figures for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223617
- http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20PD-1%20blockade%20in%20resectable%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1716078&volume=378&issue=21&pages=1976-1986&publication_year=2018&author=Forde%2CPM&author=Chaft%2CJE&author=Smith%2CKN's financial summary
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtV2rtrjL pull in monthly?
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29658856
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20plus%20chemotherapy%20in%20metastatic%20non-small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1801005&volume=378&issue=22&pages=2078-2092&publication_year=2018&author=Gandhi%2CL&author=Rodr%C3%ADguez-Abreu%2CD&author=Gadgeel%2CS have monthly?
- Monthly income for https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BB3cXjslSjurc%3D
- Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32036071 is on a monthly basis
- How much does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20PD-1%20inhibitor%20%28Sintilimab%29%20in%20NSCLC&journal=J%20Thorac%20Oncol&doi=10.1016%2Fj.jtho.2020.01.017&volume=15&issue=5&pages=816-826&publication_year=2020&author=Gao%2CS&author=Li%2CN&author=Gao%2CS net monthly?
- How much money does https://link.springer.com/doi/10.1007/s11912-020-00969-w make?
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32803520 generate?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=Striving%20toward%20improved%20outcomes%20for%20surgically%20resectable%20non-small%20cell%20lung%20cancer%3A%20the%20promise%20and%20challenges%20of%20neoadjuvant%20immunotherapy&journal=Curr%20Oncol%20Rep&doi=10.1007%2Fs11912-020-00969-w&volume=22&issue=11&pages=109-109&publication_year=2020&author=Gentzler%2CRD&author=Riley%2CDO&author=Martin%2CLW is on a monthly basis
- What's the revenue for https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BC2cXlt1SmtA%3D%3D?
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24384493?
- What's http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734624's gross income?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Pathological%20response%20after%20neoadjuvant%20chemotherapy%20in%20resectable%20non-small-cell%20lung%20cancers%3A%20proposal%20for%20the%20use%20of%20major%20pathological%20response%20as%20a%20surrogate%20endpoint&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2813%2970334-6&volume=15&issue=1&pages=e42-50&publication_year=2014&author=Hellmann%2CMD&author=Chaft%2CJE&author=William%2CWN
- How much money does https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BB3cXis1Sitrk%3D generate?
- What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31942075?
- Profit of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762581
- How much does http://scholar.google.com/scholar_lookup?&title=B%20cells%20and%20tertiary%20lymphoid%20structures%20promote%20immunotherapy%20response&journal=Nature&doi=10.1038%2Fs41586-019-1922-8&volume=577&pages=549-555&publication_year=2020&author=Helmink%2CBA&author=Reddy%2CSM&author=Gao%2CJ earn?
- How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23782644?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=A%20clinical%20risk%20model%20for%20the%20evaluation%20of%20bronchopleural%20fistula%20in%20non-small%20cell%20lung%20cancer%20after%20pneumonectomy&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2013.04.050&volume=96&issue=2&pages=419-424&publication_year=2013&author=Hu%2CXF&author=Duan%2CL&author=Jiang%2CGN is on a monthly basis
- Learn about the earnings of https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:STN:280:DC%2BD1MjhtlGisQ%3D%3D
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19853117
- How much money does http://scholar.google.com/scholar_lookup?&title=Risk%20factor%20comparison%20and%20clinical%20analysis%20of%20early%20and%20late%20bronchopleural%20fistula%20after%20non-small%20cell%20lung%20cancer%20surgery&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2009.06.024&volume=88&issue=5&pages=1589-1593&publication_year=2009&author=Jichen%2CQV&author=Chen%2CG&author=Jiang%2CG generate?
- What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27052116?
- How much profit does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20therapy%20and%20risk%20of%20bronchopleural%20fistula%20after%20lung%20cancer%20surgery%3A%20a%20systematic%20meta-analysis%20of%2014%20912%20patients&journal=Jpn%20J%20Clin%20Oncol&doi=10.1093%2Fjjco%2Fhyw037&volume=46&issue=6&pages=534-546&publication_year=2016&author=Li%2CS&author=Fan%2CJ&author=Liu%2CJ generate?
- https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BC1MXptFemtLk%3D's total income per month
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31018251's revenue stream
- How much does http://scholar.google.com/scholar_lookup?&title=PD-%20%28L%291%20inhibitors%20vs.%20chemotherapy%20vs.%20their%20combination%20in%20front-line%20treatment%20for%20NSCLC%3A%20an%20indirect%20comparison&journal=Int%20J%20Cancer&doi=10.1002%2Fijc.32366&volume=145&pages=3011-3021&publication_year=2019&author=Liang%2CH&author=Liu%2CZ&author=Cai%2CX make?
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28786099
- How much does http://scholar.google.com/scholar_lookup?&title=Current%20landscape%20of%20targeted%20therapy%20in%20lung%20cancer&journal=Clin%20Pharmacol%20Ther&doi=10.1002%2Fcpt.810&volume=102&issue=5&pages=757-764&publication_year=2017&author=Mayekar%2CMK&author=Bivona%2CTG generate monthly?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Bronchopleural%20fistula%20after%20pneumonectomy%3A%20risk%20factors%20and%20management%2C%20focusing%20on%20open%20window%20thoracostomy&journal=J%20Thorac%20Cardiovasc%20Surg&volume=S0022%E2%80%935223&issue=17&pages=31189-31193&publication_year=2017&author=Mazzella%2CA&author=Pardolesi%2CA&author=Maisonneuve%2CP?
- What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16427825?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=Video-assisted%20thoracic%20surgery%20lobectomy%3A%20experience%20with%201100%20cases&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2005.07.078&volume=81&pages=421-425&publication_year=2006&author=McKenna%2CRJ&author=Houck%2CW&author=Fuller%2CCB is on a monthly basis
- How much profit is https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BC1MXkt1els7g%3D making per month?
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28814907 each month?
- How profitable is http://scholar.google.com/scholar_lookup?&title=New%20prognostic%20biomarkers%20and%20therapeutic%20effect%20of%20bevacizumab%20for%20patients%20with%20non-small-cell%20lung%20cancer&journal=Lung%20Cancer%28Auckl%29&volume=8&pages=91-99&publication_year=2017&author=Niki%2CM&author=Yokoi%2CT&author=Kurata%2CT?
- How much income does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022989 have?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Preoperative%20chemotherapy%20for%20non-small-cell%20lung%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20individual%20participant%20data&journal=Lancet&doi=10.1016%2FS0140-6736%2813%2962159-5&volume=383&issue=9928&pages=1561-1571&publication_year=2014
- Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16926568
- How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856541 generate?
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Thoracoscopic%20lobectomy%20is%20a%20safe%20and%20versatile%20procedure%3A%20experience%20with%20500%20consecutive%20patients&journal=Ann%20Surg&doi=10.1097%2F01.sla.0000234892.79056.63&volume=244&pages=420-425&publication_year=2006&author=Onaitis%2CMW&author=Petersen%2CRP&author=Balderson%2CSS?
- Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22481232
- How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465940 generate?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Histopathologic%20response%20criteria%20predict%20survival%20of%20patients%20with%20resected%20lung%20cancer%20after%20neoadjuvant%20chemotherapy&journal=J%20Thorac%20Oncol&doi=10.1097%2FJTO.0b013e318247504a&volume=7&issue=5&pages=825-832&publication_year=2012&author=Pataer%2CA&author=Kalhor%2CN&author=Correa%2CAM?
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26303974
- Earnings of http://scholar.google.com/scholar_lookup?&title=A%20predictive%20score%20for%20bronchopleural%20fistula%20established%20using%20the%20French%20database%20epithor&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2015.06.026&volume=101&issue=1&pages=287-293&publication_year=2016&author=Pforr%2CA&author=Pages%2CPB&author=Baste%2CJM
- What's the financial gain of https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvFegtb3N?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32979984 pull in monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20chemotherapy%20and%20nivolumab%20in%20resectable%20non-small-cell%20lung%20cancer%20%28NADIM%29%3A%20an%20open-label%2C%20multicentre%2C%20single-arm%2C%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2820%2930453-8&volume=21&issue=11&pages=1413-1422&publication_year=2020&author=Provencio%2CM&author=Nadal%2CE&author=Insa%2CA rake in every month?
- What are the total earnings of http://scholar.google.com/scholar_lookup?&title=Treatment%20of%20stage%20III%20non-small%20cell%20lung%20cancer%20diagnosis%20and%20management%20of%20lung%20cancer%2C%203rd%20ed%3A%20American%20college%20of%20chest%20physicians%20evidence-based%20clinical%20practice%20guidelines&journal=Chest&doi=10.1378%2Fchest.12-2360&volume=143&issue=5&pages=E314-E340&publication_year=2013&author=Ramnath%2CN&author=Dilling%2CTJ&author=Harris%2CLJ?
- How much revenue does https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BB3cXptVCjsL4%3D produce monthly?
- Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32386568
- How much does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20atezolizumab%20and%20chemotherapy%20in%20patients%20with%20resectable%20non-small%20cell%20lung%20cancer%3A%20an%20open-label%2C%20multicentre%20single-arm%2C%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2820%2930140-6&volume=21&issue=6&pages=786-795&publication_year=2020&author=Shu%2CCA&author=Gainor%2CJF&author=Awad%2CMM pull in?
- How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27296106 making per month?
- How much does http://scholar.google.com/scholar_lookup?&title=Clinicopathologic%20features%20of%20advanced%20squamous%20NSCLC&journal=J%20Thorac%20Oncol&doi=10.1016%2Fj.jtho.2016.05.024&volume=11&issue=9&pages=1411-1422&publication_year=2016&author=Socinski%2CMA&author=Obasaju%2CC&author=Gandara%2CD generate monthly?
- Explore the financials of https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtFKkt77K
- Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29863955
- How much money does http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20for%20first-line%20treatment%20of%20metastatic%20nonsquamous%20NSCLC&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1716948&volume=378&pages=2288-2301&publication_year=2018&author=Socinski%2CMA&author=Jotte%2CRM&author=Cappuzzo%2CF make?
- How much income does https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVGit7Y%3D have?
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32001626
- What's http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789854's gross income?
- http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20checkpoint%20blockade%20for%20cancer%20immunotherapy&journal=Science&doi=10.1126%2Fscience.aax0182&volume=367&publication_year=2020&author=Topalian%2CSL&author=Taube%2CJM&author=Pardoll%2CDM income
- Discover the revenue of https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1KmsLw%3D
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23287849?
- What's the financial intake of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549050?
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Computed%20tomography%20RECIST%20assessment%20of%20histopathologic%20response%20and%20prediction%20of%20survival%20in%20patients%20with%20resectable%20non-small-cell%20lung%20cancer%20after%20neoadjuvant%20chemotherapy&journal=J%20Thorac%20Oncol&doi=10.1097%2FJTO.0b013e3182774108&volume=8&issue=2&pages=222-228&publication_year=2013&author=William%2CWN&author=Pataer%2CA&author=Kalhor%2CN
- Monthly income for http://scholar.google.com/scholar_lookup?&title=A%20first-in-human%20phase%201a%20trial%20of%20sintilimab%20%28IBI308%29%2C%20a%20monoclonal%20antibody%20targeting%20programmed%20death-1%20%28PD-1%29%2C%20in%20Chinese%20patients%20with%20advanced%20solid%20tumors&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2018.36.15_suppl.e15125&volume=36&issue=15&publication_year=2018&author=Xu%2CJ-M&author=Jia%2CR&author=Wang%2CY
- How much money does https://link.springer.com/article/10.1007/s00432-021-03896-w/articles/cas-redirect/1:CAS:528:DC%2BB3cXhs1Wrtr4%3D generate?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31194613 gross monthly?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Erlotinib%20versus%20gemcitabine%20plus%20cisplatin%20as%20neoadjuvant%20treatment%20of%20stage%20IIIA-N2%20EGFR-mutant%20non-small-cell%20lung%20cancer%20%28EMERGING-CTONG%201103%29%3A%20a%20randomized%20phase%20II%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.19.00075&volume=37&issue=25&pages=2235-2245&publication_year=2019&author=Zhong%2CWZ&author=Chen%2CKN&author=Chen%2CC generate?
- Explore the financials of https://citation-needed.springer.com/v2/references/10.1007/s00432-021-03896-w?format=refman&flavour=references
- How much profit is https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Chao%20Sun making per month?
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chao%20Sun generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chao%20Sun%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in?
- https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Yunpeng%20Liu income
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yunpeng%20Liu generate?
- What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yunpeng%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Peng%20Zhang generate monthly?
- What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Peng%20Zhang?
- What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Peng%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
- What's the monthly income of https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Xu%20Wang?
- Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xu%20Wang
- Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xu%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Profit of https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Yinghui%20Xu
- Check the income stats for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yinghui%20Xu
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yinghui%20Xu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much profit does https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Xingyu%20Lin generate?
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xingyu%20Lin?
- How much income is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xingyu%20Lin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earning monthly?
- What's the monthly income of https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Xiaobo%20Ma?
- Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiaobo%20Ma
- What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiaobo%20Ma%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the financial gain of https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Ye%20Guo?
- What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ye%20Guo?
- Learn about the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ye%20Guo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What's the income generated by https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Shi%20Qiu each month?
- What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shi%20Qiu?
- What is the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shi%20Qiu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the total monthly financial gain of https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Guoguang%20Shao?
- Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Guoguang%20Shao
- Revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Guoguang%20Shao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much money does https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Zhiguang%20Yang make?
- What's the profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zhiguang%20Yang?
- What is the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zhiguang%20Yang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://link.springer.com/article/10.1007/s00432-021-03896-w/search?sortBy=newestFirst&dc.creator=Kewei%20Ma rake in every month?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kewei%20Ma pull in?
- What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kewei%20Ma%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much profit does https://link.springer.com/article/10.1007/s00432-021-03896-w/mailto:[email protected] make?
- What's the monthly money flow for https://link.springer.com/article/10.1007/s00432-021-03896-w/mailto:[email protected]?
- What's the financial intake of https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM1_ESM.gif?
- Financial intake of https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM2_ESM.gif
- How much does https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM3_ESM.docx earn?
- What's https://s100.copyright.com/AppDispatchServlet?title=Interim%20analysis%20of%20the%20efficiency%20and%20safety%20of%20neoadjuvant%20PD-1%20inhibitor%20%28sintilimab%29%20combined%20with%20chemotherapy%20%28nab-paclitaxel%20and%20carboplatin%29%20in%20potentially%20resectable%20stage%20IIIA%2FIIIB%20non-small%20cell%20lung%20cancer%3A%20a%20single-arm%2C%20phase%202%20trial&author=Chao%20Sun%20et%20al&contentID=10.1007%2Fs00432-021-03896-w©right=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer-Verlag%20GmbH%20Germany%2C%20part%20of%20Springer%20Nature&publication=0171-5216&publicationDate=2022-02-22&publisherName=SpringerNature&orderBeanReset=true's gross income?
- What's the monthly income of https://crossmark.crossref.org/dialog/?doi=10.1007/s00432-021-03896-w?
- How much money does https://citation-needed.springer.com/v2/references/10.1007/s00432-021-03896-w?format=refman&flavour=citation make?
- What's the financial gain of https://link.springer.com/article/10.1007/s00432-021-03896-w/search?query=Non-small%20cell%20lung%20cancer&facet-discipline="Medicine%20%26%20Public%20Health"?
- How much money does https://link.springer.com/article/10.1007/s00432-021-03896-w/search?query=Neoadjuvant&facet-discipline="Medicine%20%26%20Public%20Health" make?
- How much money does https://link.springer.com/article/10.1007/s00432-021-03896-w/search?query=Chemoimmunotherapy&facet-discipline="Medicine%20%26%20Public%20Health" make?
- Financial intake of https://link.springer.com/article/10.1007/s00432-021-03896-w/search?query=Sintilimab&facet-discipline="Medicine%20%26%20Public%20Health"
- Earnings of https://link.springer.com/journals/a/1
- Learn about the earnings of https://link.springer.com/books/a/1
- Explore the financials of https://link.springer.com/journals
- How much profit does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral make?
- What's the financial outcome of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
- https://www.springernature.com/gp/products's financial summary
- How much does https://www.springernature.com/gp/librarians pull in?
- See how much https://www.springernature.com/gp/societies makes per month
- https://www.springernature.com/gp/partners's total income per month
- Earnings of https://www.springer.com/
- How much does https://www.nature.com/ generate monthly?
- https://www.biomedcentral.com/'s revenue stream
- How profitable is https://www.palgrave.com/?
- How much money does https://www.apress.com/ make?
- What is the monthly revenue of https://link.springer.com/brands/discover?
- How much does https://www.springernature.com/gp/legal/ccpa bring in each month?
- Learn about the earnings of https://www.springernature.com/gp/info/accessibility
- Get to know https://link.springer.com/termsandconditions's earnings
- Discover the revenue of https://support.springernature.com/en/support/home
- How much does https://link.springer.com/legal-notice make?
- Check the income stats for https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations
- What's the financial outcome of https://www.springernature.com/?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
- Video.js
Emails and Hosting {✉️}
Mail Servers:
- mx.zoho.eu
- mx2.zoho.eu
- mx3.zoho.eu
Name Servers:
- josh.ns.cloudflare.com
- zita.ns.cloudflare.com
CDN Services {📦}
- Crossref